Last reviewed · How we verify
JNJ-64619178
At a glance
| Generic name | JNJ-64619178 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (PHASE1)
- A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-64619178 CI brief — competitive landscape report
- JNJ-64619178 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI